Denali Therapeutics Inc.

Denali reported second-quarter AVLAYAH net product revenue of $3.6 million, its first full commercial quarter. R&D expense was $97 million versus $102.7 million a year ago, while SG&A was $36.3 million versus $32.3 million in Q2 2025, mainly due to AVLAYAH launch spending. The company ended Q2 with approximately $940 million in cash, cash equivalents, and marketable securities, and after receiving $195 million from the priority review voucher sale in July, pro forma cash exceeded $1.1 billion. For Q3, management guided AVLAYAH net product revenue to $10 million to $12 million.

Ryan Watts characterized the quarter as transformative, saying Denali became a commercial company with AVLAYAH and achieved the first proof that its transport vehicle platform can produce an approved medicine. He emphasized the platform’s breadth, highlighting a growing commercial product, a broad pipeline, and what he called a validated and scalable BBB-transport technology. His tone was upbeat but measured, repeatedly framing AVLAYAH as the beginning of a longer growth story rather than the finish line.

Alexander Schuth emphasized balance-sheet strength and capital discipline, citing about $940 million in cash, cash equivalents, and marketable securities at quarter-end and more than $1.1 billion pro forma after the $195 million PRV sale in July. He said that funding supports three priorities: AVLAYAH launch execution, preparation for DNL126 in 2027, and advancement of clinical programs, while also building internal manufacturing capabilities and preserving strategic flexibility. On expenses, he noted R&D fell to $97 million from $102.7 million year over year, while SG&A rose to $36.3 million from $32.3 million because of launch investments.

Analysts focused heavily on AVLAYAH launch dynamics, asking whether Q3 guidance implies continued growth and whether the launch is seeing a bolus effect. Management said confidence comes from strong physician awareness, family engagement, and payer progress, but acknowledged the initial patient wave is bigger than expected and that broader adoption should continue as access expands. Questions also centered on commercialization metrics, but Katie Peng said Denali is prioritizing revenue guidance over start forms or patient counts because individual journeys are highly variable. In the pipeline, analysts pressed on DNL593 timing and biomarkers, and management said it is waiting longer to better assess NfL and the broader biomarker set in hopes of maximizing the chance of an accelerated path.